Serum withdrawal after embryoid body formation does not impair cardiomyocyte development from mouse embryonic stem cells

Gianluca Testa, Carolina Tarantino, Silvia Parisi, Gianluigi Galizia, Fabiana Passaro, David Della-Morte, Pasquale Abete, Franco Rengo, Francesco Salvatore, Lucio Pastore

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background aims: Procedures for cardiomyocyte differentiation of mouse embryonic stem cells (mESCs) utilize different amounts of serum. Because the serum composition is unknown, unambiguous characterization of the differentiation process is biased. All reported serum-free protocols used for compound testing provide serum throughout the differentiation process. We report on an embryoid body (EB)-based procedure for cardiomyocyte differentiation of mESCs in which serum is provided only in the earliest step (hanging drop, 0-2 days). Methods. To assess cardiomyocyte differentiation, we generated an mESCs clone that expressed green fluorescence protein (GFP) under the control of the myosin light chain 2v (MLC2v) promoter. To define the lowest serum concentration required for efficient induction of cardiomyocyte differentiation, EBs were formed in presence of 5% (S5), 10% (S10) and 15% (S15) serum until day 2, then switched to a serum-free medium. Results. Analysis of cardiac-specific transcripts on day 6 of differentiation showed that 10% (S10) was the minimum amount of serum for efficient continuation of cultures under serum-free conditions. Spontaneously beating foci were detected in 90.0 ± 5.5% of S10 EBs on day 7 of differentiation, and cardiomyocyte markers were expressed from day 8 of differentiation (MLC2v-driven GFP; α-myosin heavy chain). Dose-response curves to isoproterenol showed that the beating rate increased by 113.0 ± 39.4%, with a concentration for half-maximal effect (EC50) of 25.7 nm. Conclusions. The development of functional cardiomyocytes from mESCs is not affected by serum withdrawal after EBs formation. This culture system represents a new model for cardiomyocyte differentiation of mESCs to assess the effects of compounds on the process of cardiomyogenesis.

Original languageEnglish
Pages (from-to)350-356
Number of pages7
JournalCytotherapy
Volume13
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Embryoid Bodies
Cardiac Myocytes
Serum
Myosin Light Chains
Fluorescence
Mouse Embryonic Stem Cells
Myosin Heavy Chains
Differentiation Antigens
Serum-Free Culture Media
Isoproterenol
Proteins
Clone Cells

Keywords

  • Cardiomyocyte differentiation
  • embryonic stem cells
  • serum

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Cite this

Serum withdrawal after embryoid body formation does not impair cardiomyocyte development from mouse embryonic stem cells. / Testa, Gianluca; Tarantino, Carolina; Parisi, Silvia; Galizia, Gianluigi; Passaro, Fabiana; Della-Morte, David; Abete, Pasquale; Rengo, Franco; Salvatore, Francesco; Pastore, Lucio.

In: Cytotherapy, Vol. 13, No. 3, 03.2011, p. 350-356.

Research output: Contribution to journalArticle

Testa, Gianluca ; Tarantino, Carolina ; Parisi, Silvia ; Galizia, Gianluigi ; Passaro, Fabiana ; Della-Morte, David ; Abete, Pasquale ; Rengo, Franco ; Salvatore, Francesco ; Pastore, Lucio. / Serum withdrawal after embryoid body formation does not impair cardiomyocyte development from mouse embryonic stem cells. In: Cytotherapy. 2011 ; Vol. 13, No. 3. pp. 350-356.
@article{78dce7dd18234b578c59b0bc4c6cc3ae,
title = "Serum withdrawal after embryoid body formation does not impair cardiomyocyte development from mouse embryonic stem cells",
abstract = "Background aims: Procedures for cardiomyocyte differentiation of mouse embryonic stem cells (mESCs) utilize different amounts of serum. Because the serum composition is unknown, unambiguous characterization of the differentiation process is biased. All reported serum-free protocols used for compound testing provide serum throughout the differentiation process. We report on an embryoid body (EB)-based procedure for cardiomyocyte differentiation of mESCs in which serum is provided only in the earliest step (hanging drop, 0-2 days). Methods. To assess cardiomyocyte differentiation, we generated an mESCs clone that expressed green fluorescence protein (GFP) under the control of the myosin light chain 2v (MLC2v) promoter. To define the lowest serum concentration required for efficient induction of cardiomyocyte differentiation, EBs were formed in presence of 5{\%} (S5), 10{\%} (S10) and 15{\%} (S15) serum until day 2, then switched to a serum-free medium. Results. Analysis of cardiac-specific transcripts on day 6 of differentiation showed that 10{\%} (S10) was the minimum amount of serum for efficient continuation of cultures under serum-free conditions. Spontaneously beating foci were detected in 90.0 ± 5.5{\%} of S10 EBs on day 7 of differentiation, and cardiomyocyte markers were expressed from day 8 of differentiation (MLC2v-driven GFP; α-myosin heavy chain). Dose-response curves to isoproterenol showed that the beating rate increased by 113.0 ± 39.4{\%}, with a concentration for half-maximal effect (EC50) of 25.7 nm. Conclusions. The development of functional cardiomyocytes from mESCs is not affected by serum withdrawal after EBs formation. This culture system represents a new model for cardiomyocyte differentiation of mESCs to assess the effects of compounds on the process of cardiomyogenesis.",
keywords = "Cardiomyocyte differentiation, embryonic stem cells, serum",
author = "Gianluca Testa and Carolina Tarantino and Silvia Parisi and Gianluigi Galizia and Fabiana Passaro and David Della-Morte and Pasquale Abete and Franco Rengo and Francesco Salvatore and Lucio Pastore",
year = "2011",
month = "3",
doi = "10.3109/14653249.2010.520311",
language = "English",
volume = "13",
pages = "350--356",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Serum withdrawal after embryoid body formation does not impair cardiomyocyte development from mouse embryonic stem cells

AU - Testa, Gianluca

AU - Tarantino, Carolina

AU - Parisi, Silvia

AU - Galizia, Gianluigi

AU - Passaro, Fabiana

AU - Della-Morte, David

AU - Abete, Pasquale

AU - Rengo, Franco

AU - Salvatore, Francesco

AU - Pastore, Lucio

PY - 2011/3

Y1 - 2011/3

N2 - Background aims: Procedures for cardiomyocyte differentiation of mouse embryonic stem cells (mESCs) utilize different amounts of serum. Because the serum composition is unknown, unambiguous characterization of the differentiation process is biased. All reported serum-free protocols used for compound testing provide serum throughout the differentiation process. We report on an embryoid body (EB)-based procedure for cardiomyocyte differentiation of mESCs in which serum is provided only in the earliest step (hanging drop, 0-2 days). Methods. To assess cardiomyocyte differentiation, we generated an mESCs clone that expressed green fluorescence protein (GFP) under the control of the myosin light chain 2v (MLC2v) promoter. To define the lowest serum concentration required for efficient induction of cardiomyocyte differentiation, EBs were formed in presence of 5% (S5), 10% (S10) and 15% (S15) serum until day 2, then switched to a serum-free medium. Results. Analysis of cardiac-specific transcripts on day 6 of differentiation showed that 10% (S10) was the minimum amount of serum for efficient continuation of cultures under serum-free conditions. Spontaneously beating foci were detected in 90.0 ± 5.5% of S10 EBs on day 7 of differentiation, and cardiomyocyte markers were expressed from day 8 of differentiation (MLC2v-driven GFP; α-myosin heavy chain). Dose-response curves to isoproterenol showed that the beating rate increased by 113.0 ± 39.4%, with a concentration for half-maximal effect (EC50) of 25.7 nm. Conclusions. The development of functional cardiomyocytes from mESCs is not affected by serum withdrawal after EBs formation. This culture system represents a new model for cardiomyocyte differentiation of mESCs to assess the effects of compounds on the process of cardiomyogenesis.

AB - Background aims: Procedures for cardiomyocyte differentiation of mouse embryonic stem cells (mESCs) utilize different amounts of serum. Because the serum composition is unknown, unambiguous characterization of the differentiation process is biased. All reported serum-free protocols used for compound testing provide serum throughout the differentiation process. We report on an embryoid body (EB)-based procedure for cardiomyocyte differentiation of mESCs in which serum is provided only in the earliest step (hanging drop, 0-2 days). Methods. To assess cardiomyocyte differentiation, we generated an mESCs clone that expressed green fluorescence protein (GFP) under the control of the myosin light chain 2v (MLC2v) promoter. To define the lowest serum concentration required for efficient induction of cardiomyocyte differentiation, EBs were formed in presence of 5% (S5), 10% (S10) and 15% (S15) serum until day 2, then switched to a serum-free medium. Results. Analysis of cardiac-specific transcripts on day 6 of differentiation showed that 10% (S10) was the minimum amount of serum for efficient continuation of cultures under serum-free conditions. Spontaneously beating foci were detected in 90.0 ± 5.5% of S10 EBs on day 7 of differentiation, and cardiomyocyte markers were expressed from day 8 of differentiation (MLC2v-driven GFP; α-myosin heavy chain). Dose-response curves to isoproterenol showed that the beating rate increased by 113.0 ± 39.4%, with a concentration for half-maximal effect (EC50) of 25.7 nm. Conclusions. The development of functional cardiomyocytes from mESCs is not affected by serum withdrawal after EBs formation. This culture system represents a new model for cardiomyocyte differentiation of mESCs to assess the effects of compounds on the process of cardiomyogenesis.

KW - Cardiomyocyte differentiation

KW - embryonic stem cells

KW - serum

UR - http://www.scopus.com/inward/record.url?scp=79951698577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951698577&partnerID=8YFLogxK

U2 - 10.3109/14653249.2010.520311

DO - 10.3109/14653249.2010.520311

M3 - Article

VL - 13

SP - 350

EP - 356

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 3

ER -